2016
DOI: 10.1016/j.apjtb.2015.10.006
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of imatinib mesylate (Gleevec) on KAI1/CD82 gene expression in breast cancer MCF-7 cells using quantitative real-time PCR

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
10
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
10

Relationship

2
8

Authors

Journals

citations
Cited by 25 publications
(10 citation statements)
references
References 24 publications
0
10
0
Order By: Relevance
“…Imatinib mesylate (STI571; Gleevec V R ; Novartis, Basel, Switzerland) is the first successful member of a new class of kinase inhibitors that acts by inhibiting specific tyrosine kineses like Bcr-Abl fusion oncoprotein in chronic myeloid leukaemia (CML), as well as inhibits the activation of platelet-derived growth factor (PDGF)ab, colony stimulating factor 1 (CSF1) receptors and ckit, which regulates major cellular events. It is currently used in research and treatment of several solid tumors (Blay and Rutkowski 2014, Sadat Shandiz et al 2016a, 2016b, Woo et al 2015. Despite the success in tyrosine kinase inhibitors for the treatment of cancer, the bioavailability of most of the small kinase inhibitors in the physiological environment is extremely poor due to hydrophobic nature (Pawson and Warner 2007).…”
Section: Introductionmentioning
confidence: 99%
“…Imatinib mesylate (STI571; Gleevec V R ; Novartis, Basel, Switzerland) is the first successful member of a new class of kinase inhibitors that acts by inhibiting specific tyrosine kineses like Bcr-Abl fusion oncoprotein in chronic myeloid leukaemia (CML), as well as inhibits the activation of platelet-derived growth factor (PDGF)ab, colony stimulating factor 1 (CSF1) receptors and ckit, which regulates major cellular events. It is currently used in research and treatment of several solid tumors (Blay and Rutkowski 2014, Sadat Shandiz et al 2016a, 2016b, Woo et al 2015. Despite the success in tyrosine kinase inhibitors for the treatment of cancer, the bioavailability of most of the small kinase inhibitors in the physiological environment is extremely poor due to hydrophobic nature (Pawson and Warner 2007).…”
Section: Introductionmentioning
confidence: 99%
“…16 Several studies were designed to explore the growth inhibitory effect of IM either in vitro (cancer cell lines) or in vivo (tumor-bearing experimental animals) on variety of cancer cell types, such as of breast, 17,18 liver, 19 prostate, 20 and colorectal origin 21 as well as many other types of malignant tumors. 22,23 Besides IM great effectiveness, patients treated with IM may suffer from its side effects and long-term toxicity as renal, cardiac, and hepatotoxicity. 24,25 In relation to autophagy pathway of cancer cells, the inhibition of autophagy was proved to increase the effect of IM and thus, by using NCs with IM treatment, the autophagy hindrance effect of NCs will give a synergistic action, which can substantially reveals a potential formulation of IM in the era of cancer treatment.…”
Section: Introductionmentioning
confidence: 99%
“…Subsequently, the resulting purple formazan crystals were dissolved in dimethyl sulfoxide and then the optical density (OD) of each well was measured. 31 The absorbance at 570 nm was evaluated using a microplate reader (Bio-Rad 680; Microplate Master, Hercules, CA, USA). The effect of NPs on the cells was expressed as the percentage of cell viability compared to control, which was calculated according to the following formula: percentage of cell viability (%) = mean OD/control OD ×100.…”
mentioning
confidence: 99%